In recent years, a number of somatically acquired mutational changes have been identified
in patients with acute myeloid leukemia (AML). Most of these genetic alterations occur in …

The heterogeneity of acute myeloid leukemia (AML) results from a complex network of
cytogenetic aberrations and molecular mutations. These genetic markers are the basis for …

The incidence of acute myeloid leukemia (AML) is increasing with age. As the results
associated with standard intensive chemotherapy remain particularly disappointing in older …

Background: All-trans retinoic acid (ATRA) is mandatory in the treatment of acute
promyelocytic leukaemia (APL). Experimental studies suggest that ATRA can induce …

Glutathione S-transferases (GSTs) are phase II detoxification enzymes involved in the
metabolism of carcinogens and anticancer drugs, known also to interact with kinase …

Preferentially expressed antigen of melanoma (PRAME) is expressed in a wide variety of
tumors, but in contrast with most other tumor associated antigens, it is also expressed in …

Currently, no standard treatment is available for elderly patients with de novo/secondary
acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy. New, less …

We describe several recent advances in our understanding and treatment of acute myeloid
leukemia (AML) and myelodysplastic syndrome (MDS) including the use of cytogenetics to …

Twenty-one acute myeloid leukemia (AML) patients were enrolled and received oral
induction therapy with cytarabine ocfosfate (SPAC) and etoposide (EP). The median age …

Acute myeloid leukemia (AML) is characterized by a block of terminal differentiation of
hematopoietic precursors and the repression of normal hematopoiesis by expanding …